Drug intelligence / Profile preview

TEV-261

Development stage: Preclinical
Lead developer: Teva Pharmaceutical Industries
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TEV-261 is a biosimilar candidate developed by Teva Pharmaceuticals that is currently in preclinical development. It is a biosimilar version of pembrolizumab (marketed as Keytruda), a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. By inhibiting the PD-1 pathway, TEV-261 aims to restore the ability of T cells to recognize and attack cancer cells. As a biosimilar, it is intended to provide a more cost-effective treatment option for the wide range of oncology indications approved for the reference product, including melanoma, non-small cell lung cancer, and various other solid tumors.

Other names: pembrolizumab biosimilarTeva pembrolizumab biosimilar

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on TEV-261.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEV-261.

Explore the full profile